Valuation: PREDILIFE

Market Cap 3.51M 3.93M 3.93M 3.27M 2.97M 5.61M 381M 5.64M 39.32M 15.41M 194M 14.77M 14.44M 623M P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 8.29M 9.28M 9.28M 7.71M 7.01M 13.24M 898M 13.3M 92.81M 36.37M 458M 34.86M 34.09M 1.47B EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 56 31/12/2003
Chief Tech/Sci/R&D Officer - 31/12/2006
General Counsel - 31/12/2015
Director TitleAgeSince
Chairman 56 31/12/2003
Director/Board Member 46 31/12/2017
Director/Board Member 58 31/12/2017
Change 5-day change 1-year change 3-year change Capi.($)
-2.59%-5.70%+39.83%+82.45% 70.61B
+3.23%-10.67%+4.87%+55.97% 51.01B
+1.56%+1.17%+5.15%+33.38% 48.1B
+0.39%+0.65%+28.02%+30.24% 42.78B
+0.87%-8.17%+298.53%+645.03% 40.67B
+1.24%-1.01%+5.56%+105.14% 40.3B
-2.13%-1.64%+7.51%+50.31% 30.59B
-0.46%-1.28%+31.47%+19.93% 28.16B
+5.32%+0.06%-7.20%-11.30% 24.36B
Average +0.83%-2.66%+45.97%+112.35% 41.84B
Weighted average by Cap. +0.56%-2.94%+47.30%+116.51%

Financials

2024 2025
Net sales 493K 552K 552K 459K 417K 788K 53.45M 791K 5.52M 2.16M 27.25M 2.07M 2.03M 87.44M 836K 936K 936K 778K 707K 1.34M 90.57M 1.34M 9.36M 3.67M 46.18M 3.51M 3.44M 148M
Net income -4.26M -4.78M -4.78M -3.97M -3.61M -6.81M -462M -6.84M -47.75M -18.71M -236M -17.93M -17.54M -756M -3.93M -4.41M -4.41M -3.66M -3.33M -6.29M -426M -6.31M -44.05M -17.26M -217M -16.54M -16.18M -698M
Net Debt 3.54M 3.96M 3.96M 3.29M 2.99M 5.65M 383M 5.68M 39.62M 15.52M 195M 14.88M 14.55M 627M 4.78M 5.35M 5.35M 4.44M 4.04M 7.63M 518M 7.67M 53.49M 20.96M 264M 20.09M 19.65M 847M
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
-